JP7821741B2 - 動物用のｉｌ４／ｉｌ１３受容体分子 - Google Patents

動物用のｉｌ４／ｉｌ１３受容体分子

Info

Publication number
JP7821741B2
JP7821741B2 JP2022563172A JP2022563172A JP7821741B2 JP 7821741 B2 JP7821741 B2 JP 7821741B2 JP 2022563172 A JP2022563172 A JP 2022563172A JP 2022563172 A JP2022563172 A JP 2022563172A JP 7821741 B2 JP7821741 B2 JP 7821741B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
il4r
less
il13r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522676A (ja
JP2023522676A5 (enExample
Inventor
シー ジアン リー，
ラム グェン，
チンイー チュー，
フォーン チエン，
リチャード チン，
ハンチュン チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco US Inc
Original Assignee
Elanco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco US Inc filed Critical Elanco US Inc
Publication of JP2023522676A publication Critical patent/JP2023522676A/ja
Publication of JP2023522676A5 publication Critical patent/JP2023522676A5/ja
Application granted granted Critical
Publication of JP7821741B2 publication Critical patent/JP7821741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/544—IL-14

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022563172A 2020-04-22 2021-04-22 動物用のｉｌ４／ｉｌ１３受容体分子 Active JP7821741B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063014090P 2020-04-22 2020-04-22
US63/014,090 2020-04-22
US202063014573P 2020-04-23 2020-04-23
US63/014,573 2020-04-23
PCT/US2021/028679 WO2021216899A1 (en) 2020-04-22 2021-04-22 Il4/il13 receptor molecules for veterinary use

Publications (3)

Publication Number Publication Date
JP2023522676A JP2023522676A (ja) 2023-05-31
JP2023522676A5 JP2023522676A5 (enExample) 2024-05-02
JP7821741B2 true JP7821741B2 (ja) 2026-02-27

Family

ID=78270112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563172A Active JP7821741B2 (ja) 2020-04-22 2021-04-22 動物用のｉｌ４／ｉｌ１３受容体分子

Country Status (10)

Country Link
US (1) US20240270819A1 (enExample)
EP (1) EP4139344A4 (enExample)
JP (1) JP7821741B2 (enExample)
KR (1) KR20230005880A (enExample)
CN (1) CN116034112A (enExample)
AU (1) AU2021259785A1 (enExample)
BR (1) BR112022021204A2 (enExample)
CA (1) CA3173927A1 (enExample)
MX (1) MX2022013149A (enExample)
WO (1) WO2021216899A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP7657548B2 (ja) 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
EP3870601A4 (en) 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
WO2025141037A1 (en) * 2023-12-28 2025-07-03 Elanco Animal Health Gmbh Il-4/il-13 and il-4/il-13/il-31 receptor trap constructs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161724A (ja) 2003-12-23 2007-06-28 Tanox Inc 新規抗ｉｌ１３抗体およびその使用
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
US20200048325A1 (en) 2017-04-21 2020-02-13 Kindred Biosciences, Inc. IL4/IL13 Receptor Molecule for Veterinary Use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) * 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
US20170290889A1 (en) * 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
KR20250137204A (ko) * 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
AU2023415535A1 (en) * 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161724A (ja) 2003-12-23 2007-06-28 Tanox Inc 新規抗ｉｌ１３抗体およびその使用
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
US20200048325A1 (en) 2017-04-21 2020-02-13 Kindred Biosciences, Inc. IL4/IL13 Receptor Molecule for Veterinary Use

Also Published As

Publication number Publication date
MX2022013149A (es) 2023-02-09
BR112022021204A2 (pt) 2022-12-06
CA3173927A1 (en) 2021-10-28
JP2023522676A (ja) 2023-05-31
US20240270819A1 (en) 2024-08-15
EP4139344A4 (en) 2024-10-16
AU2021259785A1 (en) 2022-11-17
KR20230005880A (ko) 2023-01-10
CN116034112A (zh) 2023-04-28
EP4139344A1 (en) 2023-03-01
WO2021216899A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US12428466B2 (en) IL4/IL13 receptor molecule for veterinary use
JP2025093964A (ja) 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体
JP2023522676A (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
CN113840831A (zh) 医用ngf拮抗剂
AU2019416344A1 (en) IgG Fc variants for veterinary use
JP7671275B2 (ja) 動物用の抗ｉｌ３１抗体
CN115515635A (zh) 兽用抗il4受体抗体
EP3641813A1 (en) Il17a antibodies and antagonists for veterinary use
JP7580800B2 (ja) 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
RU2795591C2 (ru) Молекула рецептора il4/il13 для ветеринарного применения
RU2850882C2 (ru) Варианты fc igg для ветеринарного применения

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260216

R150 Certificate of patent or registration of utility model

Ref document number: 7821741

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150